Corcept’s Sean Maduck exercises options at $8.27

A Corcept Therapeutics officer's reported sales were made under a Rule 10b5-1 plan adopted December 8, 2025, alongside option exercises on October 1 and October 2, 2026.

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) officer Sean Maduck reported option exercises and common-stock sales on October 1 and October 2, 2026; remarks identify him as President, Corcept Endocrinology. He exercised options for 413 shares on October 1 and 24,587 shares on October 2, each at $8.27 per share, and sold 413 shares at a weighted-average $115.5373 per share on October 1. On October 2, he sold 15,843 shares at a weighted-average $116.1233 and 8,744 shares at $116.5534 per share. The sales were made under a Rule 10b5-1 plan adopted December 8, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 25,000 shares ($2.70M approx. pre-tax spread)

Exercise and Sale 12 txns

Insider Maduck Sean

Role See Remarks

Sold 25,000 shs ($2.91M)

Approx. gross sale proceeds $2.91M

Approx. exercise cost $207K

Approx. pre-tax spread $2.70M

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) F11	24,587	$0.00	$0.00
Exercise	Common Stock F1	24,587	$8.27	$203K
Sale	Common Stock F2, F4, F1	15,843	$116.1233	$1.84M
Sale	Common Stock F2, F5, F1	8,744	$116.5534	$1.02M
Exercise	Stock option (right to buy) F11	413	$0.00	$0.00
Exercise	Common Stock F1	413	$8.27	$3K
Sale	Common Stock F2, F3, F1	413	$115.5373	$48K
holding	Common Stock F6	--	--	--
holding	Common Stock F7	--	--	--
holding	Common Stock F8	--	--	--
holding	Common Stock F9	--	--	--
holding	Common Stock F10	--	--	--

Holdings After Transaction: Stock option (right to buy) — 41,986 contracts (Direct); Common Stock — 9,938 shares (Direct); Common Stock — 109,717 shares (Indirect, See Footnote)

Footnotes (11)

1. F1. Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
6. F6. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
7. F7. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
8. F8. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
9. F9. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
10. F10. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
11. F11. Fully exercisable.

Key Figures

Options exercised: 24,587 shares Options exercised: 413 shares Option exercise price: $8.27 per share +3 more

6 metrics

Options exercised 24,587 shares October 2, 2026

Options exercised 413 shares October 1, 2026

Option exercise price $8.27 per share Options exercised October 1 and October 2, 2026

Shares sold 413 shares at weighted-average $115.5373 per share October 1, 2026

Shares sold 15,843 shares at weighted-average $116.1233 per share October 2, 2026

Shares sold 8,744 shares at $116.5534 per share October 2, 2026

Key Terms

10b5-1 plan, weighted average sale price, restricted stock awards, Fully exercisable

4 terms

10b5-1 plan financial

"made pursuant to a 10b5-1 plan"

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

weighted average sale price financial

"Represents the weighted average sale price"

restricted stock awards financial

"shares underlying unvested restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Fully exercisable financial

"Fully exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What CORT share sales did Sean Maduck report?

Sean Maduck reported sales of 413 shares at a weighted-average $115.5373 per share on October 1, 2026, and 15,843 shares at a weighted-average $116.1233 per share and 8,744 shares at $116.5534 per share on October 2, 2026. The sales were made under a Rule 10b5-1 plan adopted December 8, 2025.

What were the terms of Sean Maduck's CORT option exercises?

Maduck exercised options for 413 shares on October 1, 2026, and 24,587 shares on October 2, 2026, at $8.27 per share. The reported options were fully exercisable and had an expiration date of February 10, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 07:49 PM Accepted by SEC EDGAR 10/05/2026 - 07:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maduck Sean

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		M		413	A	$8.27	10,351(1)	D
Common Stock	10/01/2026		S(2)		413	D	$115.5373(3)	9,938(1)	D
Common Stock	10/02/2026		M		24,587	A	$8.27	34,525(1)	D
Common Stock	10/02/2026		S(2)		15,843	D	$116.1233(4)	18,682(1)	D
Common Stock	10/02/2026		S(2)		8,744	D	$116.5534(5)	9,938(1)	D
Common Stock								5,147	I	See Footnote(6)
Common Stock								20,570	I	See Footnote(7)
Common Stock								40,000	I	See Footnote(8)
Common Stock								34,000	I	See Footnote(9)
Common Stock								10,000	I	See Footnote(10)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$8.27	10/01/2026		M			413	(11)	02/10/2027	Common Stock	413	$0.00	66,573	D
Stock option (right to buy)	$8.27	10/02/2026		M			24,587	(11)	02/10/2027	Common Stock	24,587	$0.00	41,986	D

Explanation of Responses:

1. Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

6. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

7. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.

8. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

9. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

10. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

11. Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)